Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

First SYGNIS QualiPhi®-based Products Launched by QIAGEN

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
QualiPhi®, now renamed SensiPhi®, targets sophisticated applications for DNA amplification.

SYGNIS AG has announced that its partner QIAGEN has launched the first two products of a series of kits based on SYGNIS’ proprietary amplification technology QualiPhi® now renamed SensiPhi®.

The two kits, REPLI-g WTA Single Cell Kit and REPLI-g Cell WGA & WTA Kit, are available now and will be commercialized globally through QIAGEN’s established distribution channels. The product launches result from a global exclusive license agreement with QIAGEN signed in 2012.

“We are at the beginning of a series of product launches that we believe will establish our polymerase as the potential future gold standard for isothermal amplification of DNA”, Pilar de la Huerta, CEO of SYGNIS stated.

Huerta continued, “With the launch of the first products based on our proprietary technology, SYGNIS continues to deliver on its objectives. It is a mark of our success as a company to have our product commercialized by the world leader QIAGEN.”

“We are very pleased with the launch of our new kits based on the polymerase provided by SYGNIS”, commented Achim Ribbe, Vice President Corporate Business Development Licensing at QIAGEN. “The REPLI-g WTA Single Cell and REPLI-g Cell WGA & WTA address key user challenges in NGS and other downstream applications, where DNA sequence analysis is limited by small amounts down to single cells of available sample material. To drive adoption of NGS in the clinical space, QIAGEN is building a broad portfolio of universal products including the REPLI-g Single Cell Kits which are compatible with any major NGS platform and which also support our own integrated sample-to-insight GeneReader workflow currently in development.”

SensiPhi® is the second generation of a DNA polymerase that was licensed from the Spanish National Research Council (CSIC) in 2010. Due to its unique properties, first studies suggest that it has the potential to improve the amplifications of whole genomes and large stretches of DNA.

SYGNIS’ SensiPhi® is a high efficiency, high fidelity polymerase for DNA amplification which conveys the outstanding properties in terms of speed, accuracy and length of DNA fragments to be amplified.

It differs from PCR since it provides generic amplification of the complete genome, whereas PCR is designed to detect predefined target sequences, and therefore only amplifies specific, mostly very short fragments of the DNA.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS AG Signs Distribution Agreement with LABGENE Scientific
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Friday, September 18, 2015
SYGNIS AG Signs Non-Exclusive Distribution Agreement with GeneWorks Pty Ltd
Agreement covers the entire SYGNIS portfolio of powerful tools for next generation sequencing and single cell analysis applications.
Tuesday, August 25, 2015
SYGNIS AG Signs Distribution Agreement with Chinese Nanodigmbio Co. Ltd.
Distribution agreement covers the entire SYGNIS portfolio of powerful tools addressing key challenges in NGS and single cell analysis.
Saturday, August 22, 2015
SYGNIS Signs Initial Distribution Agreement with FUNAKOSHI
TruePrime™ family for whole genome amplification without the need of synthetic random primers on stock and ready for distribution in Japan.
Thursday, March 05, 2015
SYGNIS Signs Initial Non-Exclusive Distribution Agreement with BioCat
TruePrime™ Single Cell WGA kit to be launched early 2015.
Tuesday, December 30, 2014
SYGNIS Announces Double Switch Technology Patent Deal with SYSTASY
Company reiterates strategic deals with leading industry partners.
Tuesday, May 13, 2014
SYGNIS Reports Financial Results for a Successful Fiscal Year 2013
First products launched based on QualiPhi® now renamed SensiPhi® in early 2014.
Wednesday, April 02, 2014
SYGNIS AG Successfully Completes Rights Offering and Private Placement
Company plans to use EUR 2.7 million to finance its operating business and further growth.
Monday, October 28, 2013
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos